-
The same signal, different fates, the root of the difference between CD28 CAR-T and 4-1BB CAR-T
Time of Update: 2021-04-14
The research results show that CD28 and 4-1BB use the same signal pathway, but the phosphorylation level caused by CD28 activation is significantly higher than that of 4-1BB, and therefore produces a higher level of effector molecules, so CD28CAR-T has a stronger cell effect function .
-
Why are some people more likely to get cervical cancer when infected with HPV?
Time of Update: 2021-04-14
Screenshot source: The Lancet Oncology research team said that previous studies have shown that about 30% of the risk of cervical cancer is hereditary, but this is "the result of the largest genetic association study to date.
-
Long prescription for comments: 8 types of drugs were excluded, 4 cases were terminated
Time of Update: 2021-04-14
At the same time, for the first long-term prescription, it is required to be issued by a doctor with an intermediate or higher qualification for a disease-related professional in a medical institution above the second level, or by a doctor with an intermediate or higher qualification for a professional and technical position in a primary medical and health institution.
-
Guo Xiaohuan’s team reveals a new mechanism by which gut microbes promote anti-cancer drug efficacy through metabolites | Cell Press Dialogue Scientist
Time of Update: 2021-04-14
"The research paper reported that butyric acid, a metabolite of intestinal microbes, can increase the efficacy of anti-tumor drugs by enhancing the immune response of CD8+ T cells.
-
NEJM: Nivolumab adjuvant treatment program was successfully used in the Phase III clinical study of patients with advanced esophagus or gastroesophageal junction cancer
Time of Update: 2021-04-14
For patients with esophageal cancer or gastroesophageal junction cancer who need neoadjuvant chemoradiation, nivolumab adjuvant therapy is significantly better than placebo in terms of disease-free survival.
-
Qingli Xinsheng breaks advanced gastrointestinal stromal tumors——Congratulations on Qingle® (Repetinib tablets) approved in China
Time of Update: 2021-04-14
March 31, 2021-Zai Lab announced that the National Medical Products Administration (NMPA) of China has approved the marketing application of Qingle® (Repetinib tablets) for the treatment of those who have received imatinib Adult patients with advanced gastrointestinal stromal tumor (GIST) with 3 or more kinase inhibitors.
-
More than liver cancer!
Time of Update: 2021-04-14
, this study adds more evidence for the association between non-alcoholic fatty liver disease and a variety of digestive system cancers, lung cancer, and increased risk of breast cancer.
-
How can Golly Pharma enter the oncology market?
Time of Update: 2021-04-14
In the 2020 European Medical Oncology Conference (ESMO), a researcher-initiated application of the FASN inhibitor TVB-2640 (Gree code: ASC40) combined with bevacizumab for the treatment of glioblastoma II was announced Phase clinical results showed that the objective response rate (ORR) of the program reached 65%, of which the complete response rate (CR) was 20%, the partial response rate (PR) was 45%; the 6-month PFS rate was 47%, which was significantly better than Historical control (BELOB 16%, P=0.
-
JAMA Interpretation | Professor Shen Shuhong: Consolidation therapy with Bellinto Oumab in children with high-risk first relapse B-ALL significantly prolongs EFS and improves transplant prognosis
Time of Update: 2021-04-14
EFS risk of first relapse chemotherapy of B-ALL: from a randomized controlled trial of: Franco Locatelli, Gerhard Zugmaier, Carmelo Rizzari, et al Objective at high risk of first relapse in patients with B-ALL children allogeneic hematopoietic stem cell transplantation (allo- Event-free survival (EFS) after the use of belintouximab before HSCT vs.
-
Chen Shuai's team at Sun Yat-sen University discovers new potential treatment targets for colorectal cancer
Time of Update: 2021-04-14
Genomic shRNA screening identified Dyskerin pseudouridine synthase 1 (DKC1) as a previously unknown key regulator that promotes the proliferation of colorectal cancer cells.
DKC1 binds and stabilizes the mRNA of certain ribosomal proteins in a manner dependent on its pseudouridine synthase activity, thereby promoting the progression of colorectal cancer in vitro and in vivo.
-
Progress in the treatment of relapsed or refractory diffuse large B-cell lymphoma
Time of Update: 2021-04-14
This article aims to summarize the treatment progress of patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in recent years for your reference.
-
Highlights of Science Journal on April 2, 2021
Time of Update: 2021-04-14
html" target="_blank">Science: New research reveals that elevated striatal dopamine can lead to hallucinations doi:10.
html" target="_blank">Science: New research reveals increased striatal dopamine can cause hallucinations DOI: 10.
html" target="_blank">Science: New research reveals increased striatal dopamine may lead to hallucinations bioon.
-
Shanghai Yingli Pharmaceutical's PI3Kδ inhibitor Linperlisib in the treatment of relapsed/refractory follicular lymphoma Phase 2 registration clinical results are gratifying
Time of Update: 2021-04-14
Linperlisib's phase 2 clinical trial for the treatment of relapsed/refractory follicular lymphoma has achieved gratifying results, which also indicate this The new PI3Kδ selective inhibitor is expected to bring a new therapy for people suffering from this serious disease, and bring hope to these patients and their families.
-
Brand-new upgraded structure, the times prefer apatamide!
Time of Update: 2021-04-14
A new generation of non-steroidal AR inhibitor apatamide is an ideal AR inhibitor, with higher AR affinity and good tolerability, and its indications are high-risk NM-CRPC and "all types" mHSPC, more Suitable for early use of diseases.
After upgrading, a new generation of AR inhibitor apatamide has brought good survival benefits for prostate cancer patients.
-
Progress in research on platelet biomimetic formulations for combined tumor therapy
Time of Update: 2021-04-14
Inspired by this, combined with the research experience of vaccine adjuvants and tumor immunity, researcher of the Bioformulation and Biomaterials Team of the State Key Laboratory of Biochemical Engineering Ma Guanghui and Wei Weiyan proposed a new strategy for the use of platelet biomimetic formulations in the combined treatment of tumors with photothermal-immune therapy, and conducted collaborative research with Professor Tian Zhiyuan of the National University of Science and Technology.
-
Professor Lu Shun led the first-line treatment of lung cancer, and the third-generation EGFR-TKI Ametinib phase 3 clinical trial reached the primary endpoint
Time of Update: 2021-04-14
▎ WuXi AppTec's content team reported that today (March 30), Hausen Pharmaceuticals announced that its third-generation EGFR-TKI ametinib (trade name: Amelox) was the first-line treatment for EGFR mutation-positive locally advanced or metastatic non- Positive results were obtained in the phase 3 study of small cell lung cancer (NSCLC), reaching the preset primary research endpoint.
-
Express | Blood test found "King of Cancer", unique early screening test was recognized by FDA as a breakthrough medical device
Time of Update: 2021-04-14
The early screening test developed by Bluestar Genomics is a liquid biopsy designed based on circulating cell-free DNA combined with machine learning.
The liquid biopsy designed by Bluestar Genomics detects early pancreatic cancer by detecting changes in a biomarker called hydroxymethylcytosine (5hmC) on circulating cell-free DNA.
-
The 62-year-old man's stomach cancer and esophageal cancer are "ridden", which is actually related to this Zhejiangese favorite food
Time of Update: 2021-04-14
Not long ago, it was Professor Teng who performed surgery for him, removed the esophageal tumor, and transposed part of the colon to replace the esophagus with precise sutures, allowing him to eat freely again.
-
Science Advances | Open up new ideas!
Time of Update: 2021-04-14
Therefore, in order to improve these methods, it is of utmost importance to develop new PTT-based drugs, which should be reliably enriched and penetrated to the tumor site, and show higher therapeutic efficacy through additive or even synergistic effects.
-
Innovent's PI3Kδ inhibitor Parsaclisib was approved as a breakthrough therapy drug by CDE for the treatment of relapsed or refractory follicular lymphoma
Time of Update: 2021-04-14
At the 62nd American Annual Meeting of Hematology (ASH) in 2020, Incyte reported the data of a clinical study of Parsaclisib in the treatment of relapsed/refractory follicular lymphoma.
Incyte also plans to conduct trials to evaluate parsaclisib combined with tafasitamab in the treatment of non-Hodgkin's lymphoma (NHL) and chronic myeloid leukemia (CLL).
